Justin S. Michael, Bong-Seop Lee, Miqin Zhang and John S. Yu
, 4 ] With such a short median survival, it is essential that we uncover novel techniques to treat patients with GBM. Current research shows that the genetic profile of GBM is leading to resistance to TMZ and radiation, but a major battle in the treatment of GBM is drug delivery across the blood–brain barrier (BBB). There is hope for patients with GBM because nanotechnology has been able to demonstrate the ability to cross the BBB.
A number of nanomaterials, including liposomes, nanoemulsion, polymeric micelles, and iron oxide nanoparticles (IONP) have been
in patients with chronic renal insufficiency. Chin J Pract Intern Med 2011;31:333-5.
13. Kerr P, Perkovic V, Petrie J, Agar J, Disney A, Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Dialysis adequacy (HD) guidelines. Nephrology (Carlton) 2005;10 (Suppl 4):S61-80.
14. Suranyi M, Chow JS. Review: Anticoagulation for haemodialysis. Nephrology (Carlton) 2010;15:386-92.
15. Stevens KN, Croes S, Boersma RS, Stobberingh EE, van der Marel C, van der Veen FH, et al. Hydrophilic surface coatings with embedded biocidal silver nanoparticles and